List of Vivlodex drug patents

Vivlodex is owned by Iceutica Operations.

Vivlodex contains Meloxicam.

Vivlodex has a total of 3 drug patents out of which 0 drug patents have expired.

Vivlodex was authorised for market use on 22 October, 2015.

Vivlodex is available in capsule;oral dosage forms.

Vivlodex can be used as management of osteoarthritis pain by administering 10 mg of meloxicam; management of osteoarthritis pain by administering 5 mg of meloxicam.

The generics of Vivlodex are possible to be released after 31 March, 2035.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9526734 ICEUTICA OPERATIONS Formulation of meloxicam
Mar, 2033

(10 years from now)

US9808468 ICEUTICA OPERATIONS Formulation of meloxicam
Mar, 2035

(12 years from now)

US9649318 ICEUTICA OPERATIONS Formulation of meloxicam
Mar, 2035

(12 years from now)

Drugs and Companies using MELOXICAM ingredient

Market Authorisation Date: 22 October, 2015

Treatment: Management of osteoarthritis pain by administering 10 mg of meloxicam; Management of osteoarthritis pain by administering 5 mg of meloxicam

Dosage: CAPSULE;ORAL

How can I launch a generic of VIVLODEX before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic